Connection

Co-Authors

This is a "connection" page, showing publications co-authored by KELLY K HUNT and ALEXANDER LAZAR.
Connection Strength

1.130
  1. Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. Ann Surg Oncol. 2014 Aug; 21(8):2499-505.
    View in: PubMed
    Score: 0.124
  2. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer. 2011 Jan 15; 117(2):380-9.
    View in: PubMed
    Score: 0.097
  3. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Feb 13.
    View in: PubMed
    Score: 0.062
  4. Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. Cancer Res. 2023 03 15; 83(6):939-955.
    View in: PubMed
    Score: 0.058
  5. Re-excision After Unplanned Excision of Soft Tissue Sarcoma is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease. Ann Surg Oncol. 2022 Sep 09.
    View in: PubMed
    Score: 0.056
  6. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer. 2022 06 15; 150(12):2012-2024.
    View in: PubMed
    Score: 0.054
  7. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol. 2021 09; 142(3):565-590.
    View in: PubMed
    Score: 0.052
  8. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open. 2021 03 01; 4(3):e210945.
    View in: PubMed
    Score: 0.050
  9. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer. 2018 Sep 24; 18(1):913.
    View in: PubMed
    Score: 0.042
  10. Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol. 2018 Apr; 117(5):879-885.
    View in: PubMed
    Score: 0.041
  11. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology. 2018; 7(2):e1385689.
    View in: PubMed
    Score: 0.040
  12. Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surg. 2016 Apr; 151(4):347-54.
    View in: PubMed
    Score: 0.036
  13. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. Ann Surg Oncol. 2016 07; 23(7):2220-8.
    View in: PubMed
    Score: 0.035
  14. Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. Cancer. 2015 Oct 15; 121(20):3659-67.
    View in: PubMed
    Score: 0.034
  15. Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions. Ann Surg Oncol. 2015 Nov; 22(12):3913-20.
    View in: PubMed
    Score: 0.033
  16. Mesenchymal to epithelial transition in sarcomas. Eur J Cancer. 2014 Feb; 50(3):593-601.
    View in: PubMed
    Score: 0.030
  17. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol. 2013 Jul; 20(7):2364-72.
    View in: PubMed
    Score: 0.029
  18. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013 Apr; 20(4):1267-74.
    View in: PubMed
    Score: 0.028
  19. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res. 2012 Sep 01; 18(17):4633-45.
    View in: PubMed
    Score: 0.028
  20. Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug. Mol Cell Proteomics. 2010 Nov; 9(11):2405-13.
    View in: PubMed
    Score: 0.024
  21. Angiosarcoma: clinical and molecular insights. Ann Surg. 2010 Jun; 251(6):1098-106.
    View in: PubMed
    Score: 0.024
  22. Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. Cancer. 2009 Jul 01; 115(13):2971-9.
    View in: PubMed
    Score: 0.022
  23. Complete soft tissue sarcoma resection is a viable treatment option for select elderly patients. Ann Surg Oncol. 2009 Sep; 16(9):2579-86.
    View in: PubMed
    Score: 0.022
  24. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol. 2009 Sep; 16(9):2502-9.
    View in: PubMed
    Score: 0.022
  25. Increased vascular endothelial growth factor-C expression is insufficient to induce lymphatic metastasis in human soft-tissue sarcomas. Clin Cancer Res. 2009 Apr 15; 15(8):2637-46.
    View in: PubMed
    Score: 0.022
  26. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009 Apr; 16(4):910-9.
    View in: PubMed
    Score: 0.021
  27. Genetic aberrations of gastrointestinal stromal tumors. Cancer. 2008 Oct 01; 113(7):1532-43.
    View in: PubMed
    Score: 0.021
  28. Genetic aberrations in soft tissue leiomyosarcoma. Cancer Lett. 2009 Mar 08; 275(1):1-8.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.